Nkarta (NKTX) Non-Current Assets (2019 - 2026)
Nkarta's quarterly Non-Current Assets came in at $136.2 million in Q1 2026, down 31.58% year-on-year from $199.1 million in Q1 2025, and up 11.91% quarter-over-quarter from $121.7 million in Q4 2025.
Nkarta has reported Non-Current Assets for 8 years, with the latest figure at $136.2 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 31.58% year-over-year to $136.2 million; the trailing twelve-month figure through Mar 2026 stood at $547.6 million (down 38.55% YoY), and the FY2025 full-year result was $121.7 million, down 46.59% from the prior year.
- Non-Current Assets for Q1 2026 stood at $136.2 million, up from $121.7 million in the prior quarter.
- The five-year high for Non-Current Assets was $241.9 million in Q3 2024, with the low at $83.1 million in Q1 2022.
- Average Non-Current Assets over 5 years is $145.7 million, with a median of $134.2 million recorded in 2024.
- Year-over-year, Non-Current Assets surged 299.14% in 2022 and slumped 46.59% in 2025.
- Tracing NKTX's Non-Current Assets over 5 years: stood at $112.2 million in 2022, then grew by 12.08% to $125.8 million in 2023, then soared by 81.11% to $227.9 million in 2024, then plunged by 46.59% to $121.7 million in 2025, then climbed by 11.91% to $136.2 million in 2026.
- The last three Non-Current Assets figures came in at $136.2 million (Q1 2026), $121.7 million (Q4 2025), and $138.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 136.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 136.19 Mn |
| Dec 31, 2025 | 121.70 Mn |
| Sep 30, 2025 | 137.96 Mn |
| Jun 30, 2025 | 151.74 Mn |
| Mar 31, 2025 | 199.06 Mn |
| Dec 31, 2024 | 227.87 Mn |
| Sep 30, 2024 | 241.88 Mn |
| Jun 30, 2024 | 222.29 Mn |
| Mar 31, 2024 | 134.16 Mn |
| Dec 31, 2023 | 125.81 Mn |
| Sep 30, 2023 | 124.68 Mn |
| Jun 30, 2023 | 142.30 Mn |
| Mar 31, 2023 | 125.98 Mn |
| Dec 31, 2022 | 112.25 Mn |
| Sep 30, 2022 | 102.88 Mn |
| Jun 30, 2022 | 86.26 Mn |
| Mar 31, 2022 | 83.08 Mn |
| Dec 31, 2021 | 28.12 Mn |
| Sep 30, 2021 | 27.83 Mn |
| Jun 30, 2021 | 25.18 Mn |
| Mar 31, 2021 | 23.46 Mn |
| Dec 31, 2020 | 18.82 Mn |
| Sep 30, 2020 | 18.90 Mn |
| Jun 30, 2020 | 21.32 Mn |
| Dec 31, 2019 | 10.95 Mn |